Hostname: page-component-6bf8c574d5-b4m5d Total loading time: 0 Render date: 2025-02-23T14:47:18.128Z Has data issue: false hasContentIssue false
  • English
  • Français

NeuroAIDS: An Evolving Epidemic

Published online by Cambridge University Press:  02 December 2014

Christopher Power ,
Lysa Boissé ,
Sean Rourke  and
M. John Gill
Christopher Power*
Affiliation:
Departments of Medicine, Medical Microbiology and Immunology, Psychiatry, University of Alberta, Edmonton
Lysa Boissé
Affiliation:
Department of Medicine, Queen’s University, Kingston
Sean Rourke
Affiliation:
Department of Psychiatry, University of Toronto, St. Michael’s Hospital, Toronto, ON, Canada
M. John Gill
Affiliation:
Departments of Medicine, Microbiology and Infectious Diseases, University of Calgary, Calgary, AB
*
Department of Medicine (Neurology), 6-11 Heritage Medical Research Centre, University of Alberta, Edmonton, Alberta, T6G 2S2, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Over 60,000 Canadians are infected with human immunodeficiency virus (HIV). Greater than 50% of these individuals will develop a neurological disorder despite the availability of highly active antiretroviral therapy. HIV causes nervous system disease at all stages of infection with adverse effects on quality of life, adherence to medications, employment and survival. These disorders include opportunistic infections in addition to distinct HIV-associated neurological syndromes and undesirable treatment-related effects. The latter two groups of disorders are often undiagnosed and untreated in both adolescents and adults. Direct HIV infection of central nervous system causes HIV-associated dementia, which is a progressive subcortical dementia. HIV infection of the peripheral nervous system produces a painful sensory neuropathy termed distal sensory polyneuropathy, which may be exacerbated by several antiretroviral drugs. Other important HIV-induced neurological disorders include vacuolar myelopathy and an increased risk of seizures. Future issues that will confound the presentation and treatment of HIV-induced nervous system disorders include the increasing prevalence of drug-resistant HIV strains, increasing age of HIV-infected patients, hepatitis C virus co-infection and the Immune Reconstitution Inflammatory Syndrome. Herein, we review the clinical presentations, underlying pathogenesis and treatments of this burgeoning group of neurological disorders.

Type
Review Article
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 3 , May 2009 , pp. 285 - 295
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1. McArthur, JC, Brew, BJ, Nath, A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543–55.Google Scholar
2. World Health Organization “3 by 5” Progress Report, December 2004. World Health Organization and Joint United Nations Programme on HIV/AIDS; 2004.Google Scholar
3. Yeung, H, Krentz, HB, Gill, MJ, Power, C. Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. AIDS. 2006 Oct 24;20(16):2005–9.CrossRefGoogle ScholarPubMed
4. Mamidi, A, DeSimone, JA, Pomerantz, RJ. Central nervous system infections in individuals with HIV-1 infection. J Neurovirol. 2002 Jun;8(3):158–67.Google Scholar
5. Roullet, E. Opportunistic infections of the central nervous system during HIV-1 infection (emphasis on cytomegalovirus disease). J Neurol. 1999 Apr;246(4):237–43.CrossRefGoogle ScholarPubMed
6. Pandya, R, Krentz, HB, Gill, MJ, Power, C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci. 2005 May;32(2):201–4.Google Scholar
7. Power, C, Gill, MJ, Johnson, RT. The neuropathogenesis of HIV infection: host-virus interaction and the impact of therapy. Can J Neuro Sci. 2002;29(1):19–32.Google Scholar
8. Johnson, RT. Viral Infections of the nervous system. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998.Google Scholar
9. Antinori, A, Arendt, G, Becker, JT, Brew, BJ, Byrd, DA, Cherner, M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007 Oct 30;69(18):1789–99.Google Scholar
10. Jones, G, Power, C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis. 2006 Jan;21(1):1–17.CrossRefGoogle ScholarPubMed
11. Navia, BA, Cho, ES, Petito, CK, Price, RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol. 1986;19(6): 525–35.Google Scholar
12. Sharer, LR. Pathology of HIV-1 infection of the central nervous system. A review. J Neuropathol Exp Neurol. 1992;51(1):3–11.Google Scholar
13. Vinters, HV, Anders, KH. Neuropathology of AIDS. Boca Raton, Florida: CRC Press, Inc.; 1990.Google Scholar
14. McCarthy, BG, Hsieh, ST, Stocks, A, Hauer, P, Macko, C, Cornblath, DR, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology. 1995;45(10):1848–55.CrossRefGoogle ScholarPubMed
15. Herrmann, DN, Griffin, JW, Hauer, P, Cornblath, DR, McArthur, JC. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology. 1999;53(8):1634–40.Google Scholar
16. van Marle, G, Power, C. Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant? J Neurovirol. 2005;11(2):107–28.Google Scholar
17. Sacktor, N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002 Dec;8 Suppl 2:115–21.Google Scholar
18. Navia, BA, Jordan, BD, Price, RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517–24.Google Scholar
19. Mirsattari, SM, Power, C, Nath, A. Parkinsonism with HIV infection. Mov Disord. 1998;13(4):684–9.CrossRefGoogle ScholarPubMed
20. Maher, J, Choudhri, S, Halliday, W, Power, C, Nath, A. AIDS dementia complex with generalized myoclonus. Mov Disord. 1997;12(4): 593–7.CrossRefGoogle ScholarPubMed
21. Koutsilieri, E, Scheller, C, Sopper, S, ter Meulen, V, Riederer, P. Psychiatric complications in human immunodeficiency virus infection. J Neurovirol. 2002 Dec;8 Suppl 2:129–33.Google Scholar
22. Alciati, A, Fusi, A, D’Arminio Monforte, A, Coen, M, Ferri, A, Mellado, C. New-onset delusions and hallucinations in patients infected with HIV. J Psychiatry Neurosci. 2001 May;26(3):229–34.Google Scholar
23. Power, C, McArthur, JC, Johnson, RT, Griffin, DE, Glass, JD, Perryman, S, et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol. 1994;68(7): 4643–9.CrossRefGoogle ScholarPubMed
24. Brew, BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS. 2004 Jan 1;18 Suppl 1:S75–8.CrossRefGoogle ScholarPubMed
25. Ellis, RJ, Deutsch, R, Heaton, RK, Marcotte, TD, McCutchan, JA, Nelson, JA, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol. 1997;54(4):416–24.Google Scholar
26. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders [see comments]. Neurology. 1998;50(3):645–51.Google Scholar
27. Ellis, R, Langford, D, Masliah, E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci. 2007 Jan;8(1):33–44.Google Scholar
28. Heaton, RK, Marcotte, TD, Mindt, MR, Sadek, J, Moore, DJ, Bentley, H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004 May;10(3):317–31.Google Scholar
29. Heaton, RK, Velin, RA, McCutchan, JA, Gulevich, SJ, Atkinson, JH, Wallace, MR, et al. Neuropsychological impairment in human immunodeficiency virus- infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center [see comments]. Psychosom Med. 1994;56(1):8–17.CrossRefGoogle Scholar
30. McArthur, JC, Hoover, DR, Bacellar, H, Miller, EN, Cohen, BA, Becker, JT, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–52.Google Scholar
31. Tozzi, V, Balestra, P, Serraino, D, Bellagamba, R, Corpolongo, A, Piselli, P, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005 Aug;21(8):706–13.CrossRefGoogle Scholar
32. Hinkin, CH, Hardy, DJ, Mason, KI, Castellon, SA, Durvasula, RS, Lam, MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004 Jan 1;18 Suppl 1:S19–25.Google Scholar
33. Barclay, TR, Hinkin, CH, Castellon, SA, Mason, KI, Reinhard, MJ, Marion, SD, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol. 2007 Jan;26(1):40–9.Google Scholar
34. Simpson, DM, Tagliati, M. Neurologic manifestations of HIV infection [published erratum appears in Ann Intern Med 1995 Feb 15;122(4):317]. Ann Intern Med. 1994;121(10): 769–85.Google Scholar
35. Dal Pan, GJ, McArthur, JH, Aylward, E, Selnes, OA, Nance-Sproson, TE, Kumar, AJ, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology. 1992;42(11):2125–30.Google Scholar
36. McArthur, JC, Cohen, BA, Farzedegan, H, Cornblath, DR, Selnes, OA, Ostrow, D, et al. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. Ann Neurol. 1988;23 Suppl:S34–7.CrossRefGoogle ScholarPubMed
37. Sacktor, N, Skolasky, RL, Ernst, T, Mao, X, Selnes, O, Pomper, MG, et al. A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia. J Magn Reson Imaging. 2005 Apr;21(4):325–33.Google Scholar
38. Ernst, T, Chang, L, Arnold, S. Increased glial metabolites predict increased working memory network activation in HIV brain injury. Neuroimage. 2003 Aug;19(4):1686–93.Google Scholar
39. Wang, GJ, Chang, L, Volkow, ND, Telang, F, Logan, J, Ernst, T, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain. 2004 Nov;127(Pt 11):2452–8.CrossRefGoogle ScholarPubMed
40. Skinner, S, Adewale, A, DeBlock, L, Gill, MJ, Power, C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Medicine. In press 2008.CrossRefGoogle Scholar
41. Power, C, Selnes, OA, Grim, JA, McArthur, JC. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(3):273–8.CrossRefGoogle Scholar
42. Sacktor, NC, Wong, M, Nakasujja, N, Skolasky, RL, Selnes, OA, Musisi, S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005 Sep 2;19(13):1367–74.Google Scholar
43. Jones, BN, Teng, EL, Folstein, MF, Harrison, KS. A new bedside test of cognition for patients with HIV infection. Ann Intern Med. 1993 Nov 15;119(10):1001–4.CrossRefGoogle ScholarPubMed
44. Berghuis, JP, Uldall, KK, Lalonde, B. Validity of two scales in identifying HIV-associated dementia. J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):134–40.Google Scholar
45. Grassi, MP, Perin, C, Borella, M, Mangoni, A. Assessment of cognitive function in asymptomatic HIV-positive subjects. Eur Neurol. 1999;42(4):225–9.Google Scholar
46. Price, RW, Brew, BJ. The AIDS dementia complex. J Infect Dis. 1988;158(5):1079–83.CrossRefGoogle ScholarPubMed
47. Price, RW, Yiannoutsos, T, Clifford, DB, Zaborski, L, Tselis, A, Sidtis, JJ, et al. Neurological outcomes in late HIV infection:adverse impact of neurological survival and protection effect of antiretroviral therapy. AIDS. 1999;13:1677–85.Google Scholar
48. Sacktor, NC, Lyles, RH, Skolasky, RL, Anderson, DE, McArthur, JC, McFarlane, G, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology. 1999;52(8):1640–7.CrossRefGoogle ScholarPubMed
49. von Giesen, HJ, Koller, H, Theisen, A, Arendt, G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):363–7.Google Scholar
50. Nath, A, Berger, J. HIV Dementia. Curr Treat Options Neurol. 2004 Mar;6(2):139–51.Google Scholar
51. Letendre, S, Marquie-Beck, J, Capparelli, E, Best, B, Clifford, D, Collier, AC et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 Jan; 65(1):65–70.Google Scholar
52. Langford, D, Marquie-Beck, J, de Almeida, S, Lazzaretto, D, Letendre, S, Grant, I, et al. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol. 2006 Apr;12 (2):100–7.Google Scholar
53. Letendre, SL, McCutchan, JA, Childers, ME, Woods, SP, Lazzaretto, D, Heaton, RK, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56(3):416–23.CrossRefGoogle ScholarPubMed
54. Brew, BJ, Halman, M, Catalan, J, Sacktor, N, Price, RW, Brown, S, et al. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin Trials. 2007;2(3):e13.Google Scholar
55. Schifitto, G, Zhang, J, Evans, SR, Sacktor, N, Simpson, D, Millar, LL, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007 Sep 25;69(13):1314–21.Google Scholar
56. Schifitto, G, Navia, BA, Yiannoutsos, CT, Marra, CM, Chang, L, Ernst, T, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007 Sep 12;21(14):1877–86.Google Scholar
57. Zhang, K, McQuibban, GA, Silva, C, Butler, GS, Johnston, JB, Holden, J, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neuro-degeneration. Nat Neurosci. 2003;6(10):1064–71.Google Scholar
58. Silva, C, Zhang, K, Tsutsui, S, Holden, JK, Gill, MJ, Power, C. Growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression. Ann Neurol. 2003;54(5):605–14.Google Scholar
59. Zink, MC, Uhrlaub, J, DeWitt, J, Voelker, T, Bullock, B, Mankowski, J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA. 2005;293(16):2003–11.Google Scholar
60. Schifitto, G, Peterson, DR, Zhong, J, Ni, H, Cruttenden, K, Gaugh, M, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006 Mar 28;66(6):919–21.Google Scholar
61. Cysique, LA, Maruff, P, Brew, BJ. Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol. 2006;6:42.Google Scholar
62. Venkataramana, A, Pardo, CA, McArthur, JC, Kerr, DA, Irani, DN, Griffin, JW, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology. 2006 Aug 8;67(3):383–8.Google Scholar
63. McCombe, JA, Auer, RN, Maingat, FG, Houston, S, Gill, MJ, Power, C. Neurological immune reconstitution inflammatory syndrome in HIV/AIDS: outcomes and epidemiology. Neurology. 2009 Mar 3;72(9):835–41.CrossRefGoogle ScholarPubMed
64. Miller, RF, Isaacson, PG, Hall-Craggs, M, Lucas, S, Gray, F, Scaravilli, F, et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol (Berl). 2004 Jul;108(1):17–23.Google Scholar
65. Dalakas, MC, Cupler, EJ. Neuropathies in HIV infection. Baillieres Clin Neurol. 1996;5(1):199–218.Google Scholar
66. Di Rocco, A. Diseases of the spinal cord in human immunodeficiency virus infection. Semin Neurol. 1999;19(2):151–5.Google Scholar
67. Kellinghaus, C, Engbring, C, Kovac, S, Möddel, G, Boesebeck, F, Fischera, M, et al. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008 Jan;17(1): 27–33.Google Scholar
68. Keswani, SC, Pardo, CA, Cherry, CL, Hoke, A, McArthur, JC. HIV-associated sensory neuropathies. AIDS. 2002;16(16):2105–17.Google Scholar
69. Fuller, GN, Jacobs, JM, Guiloff, RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. J Neurol Neurosurg Psychiatry. 1993;56(4):372–81.Google Scholar
70. Pettersen, JA, Jones, G, Worthington, C, Krentz, HB, Keppler, OT, Hoke, A, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006 May;59(5):816–24.Google Scholar
71. Cornblath, DR, Hoke, A. Recent advances in HIV neuropathy. Curr Opin Neurol. 2006 Oct;19(5):446–50.CrossRefGoogle ScholarPubMed
72. Pardo, CA, McArthur, JC, Griffin, JW. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst. 2001;6(1):21–7.Google Scholar
73. Herrmann, DN, McDermott, MP, Sowden, JE, Henderson, D, Messing, S, Cruttenden, K, et al. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neurology. 2006 Mar 28;66(6):857–61.Google Scholar
74. Zhu, Y, Antony, JM, Martinez, JA, Glerum, DM, Brussee, V, Hoke, A, et al. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain. 2007 Aug;130(Pt 8):2011–23.Google Scholar
75. Mendell, JR, Sahenk, Z. Clinical practice. Painful sensory neuropathy. N Engl J Med. 2003 Mar 27; 348(13):1243–55.Google Scholar
76. Hahn, K, Arendt, G, Braun, JS, von Giesen, HJ, Husstedt, IW, Maschke, M, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol. 2004 Oct;251(10):1260–6.CrossRefGoogle ScholarPubMed
77. Kieburtz, K, Simpson, D, Yiannoutsos, C, Max, MB, Hall, CD, Ellis, RJ, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology. 1998 Dec;51(6):1682–8.Google Scholar
78. Simpson, DM, Estanislao, L, Brown, SJ, Sampson, J. An open-label pilot study of high-concentration capsaicin patch in painful HIV Neuropathy. J Pain Symptom Manage. 2008 Mar;35(3):299–306.Google Scholar
79. Schifitto, G, Yiannoutsos, C, Simpson, DM, Adornato, BT, Singer, EJ, Hollander, H, et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology. 2001 Oct 9;57(7):1313–6.Google Scholar
80. Vendrely, A, Bienvenu, B, Gasnault, J, Thiebault, JB, Salmon, D, Gray, F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl). 2005. Apr; 109(4)449–55.Google Scholar
81. Smit, TK, Brew, BJ, Tourtellotte, W, Morgello, S, Gelman, BB, Saksena, NK. Independent evolution of human immuno-deficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol. 2004 Sep;78 (18):10133–48.Google Scholar
82. Letendre, S, Paulino, AD, Rockenstein, E, Adame, A, Crews, L, Cherner, M, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007 Aug 1;196(3):361–70.Google Scholar
83. Centers for Disease Control-1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR. 1992;41 (RR-17):1–19.Google Scholar
84. Brew, BJ. HIV Neurology. Oxford University Press; 2001: p. 49.Google Scholar
85. Mirsattari, SM, Power, C, Nath, A. Primary headaches in HIV-infected patients. Headache. 1999 Jan;39(1):3–10.Google Scholar
86. Estanislao, LB, Morgello, S, Simpson, DM. Peripheral neuropathies associated with HIV and hepatitis C co-infection: a review. AIDS. 2005 Oct;19 Suppl 3:S135–9.Google Scholar
87. Moulignier, A, Authier, FJ, Baudrimont, M, Pialoux, G, Belec, L, Polivka, M, et al. Peripheral neuropathy in human immunodeficiency virus-infected patients with the diffuse infiltrative lymphocytosis syndrome. Ann Neurol. 1997 Apr;41 (4):438–45.Google Scholar
88. Schleicher, GK, Black, A, Mochan, A, Richards, GA. Effect of human immunodeficiency virus on intensive care unit outcome of patients with Guillain-Barre syndrome. Crit Care Med. 2003 Jun;31(6):1848–50.Google Scholar
89. Verma, A, Berger, JR. ALS syndrome in patients with HIV-1 infection. J Neurol Sci. 2006 Jan 15;240(1-2):59–64.Google Scholar
90. Evenhouse, M, Haas, E, Snell, E, Visser, J, Pawl, L, Gonzalez, R. Hypotension in infection with the human immunodeficiency virus. Ann Intern Med. 1987 Oct;107(4):598–9.CrossRefGoogle ScholarPubMed
91. Gluck, T, Degenhardt, E, Scholmerich, J, Lang, B, Grossmann, J, Straub, RH. Autonomic neuropathy in patients with HIV: course, impact of disease stage, and medication. Clin Auton Res. 2000 Feb;10(1):17–22.Google Scholar
92. Verma, S, Micsa, E, Estanislao, L, Simpson, D. Neuromuscular complications in HIV. Curr Neurol Neurosci Rep. 2004 Jan;4 (1):62–7.Google Scholar
93. Grant, I. Neurocognitive disturbances in HIV. Int Rev Psychiatry. 2008 Feb;20(1):33–47.Google Scholar
94. Price, RW. Neurological complications of HIV infection. Lancet. 1996;348(9025):445–52.Google Scholar